Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere's Q4 Loss Rises on Higher Expenses

NEW YORK (GenomeWeb News) – Nanosphere reported after the market closed Thursday that its fourth-quarter revenues dipped slightly while its net loss jumped 56 percent on higher SG&A costs.
 
The Northbrook, Ill.-based molecular diagnostics firm, which went public through an IPO in early November, said that its revenues for the three-month period ended Dec. 31 were $188,186 compared to $203,345 in the fourth quarter of 2006. Most of its revenues were from grants and government contracts.
 
The company’s net loss increased to $11.7 million, or $.84 per share, from $7.5 million, or $8.08 per share, a year ago, when it was a privately held company.
 
Nanosphere’s R&D spending was relatively flat at $5.5 million versus $5.4 million in the comparable period of 2006, while its SG&A costs nearly tripled to $3.8 million from $1.3 million. The firm has been building up its sales and marketing force to support initial sales of its Verigene System and molecular diagnostic assays.
 
The company’s Verigene platform, a hyper-coagulation panel that runs on the system, and a warfarin metabolism test were all cleared for US marketing by the Food and Drug Administration during the third quarter of 2007.
 
For full-year 2007, Nanosphere had revenues of $1.2 million, up from $1.1 million in 2006. Its net loss increased to $59.2 million, or $14.16 per share, from $45.7 million, or $52.78 per share, year over year.
 
Nanosphere’s 2007 R&D spending was $21.4 million versus $17.4 million in 2006, while its SG&A costs rose to $13.4 million from $5.4 million.
 
The firm finished the year with $114.3 million in cash.
 

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.